Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Arcellx, Inc.

Latest From Arcellx, Inc.

Novartis Hopes To Breathe New Life Into CAR-T Business With ASCO Myeloma Data

Gilead’s Kite has taken a lead in multiple myeloma cell therapy while Novartis’s first-to-market Kymriah has slumped in sales, but the Swiss drug maker’s new data may support its effort to win on manufacturing time.

ASCO Interviews

Gracell Revs FasTCar To Catch Big Pharma Rivals In Myeloma

The Chinese company’s share price has trebled in the last month thanks to impressive data at ASCO and EHA, but Gracell will need to burn rubber to close in on the frontrunners.

Cancer Clinical Trials

Gilead’s Kite Hopes To Reinforce Commercial CAR-T Lead With Yescarta Data

The company presented results from the ZUMA-7 trial at ASCO for the CAR-T therapy in the curative setting of large B-cell lymphoma.

ASCO Interviews

Gilead Reports 61 Clinical Programs Under Way, With Over 20 In Phase III

Excluding sales declines due to Veklury, Gilead said its year-over-year sales grew 15% in the first quarter, with HIV drug Biktarvy serving as the biggest driver.

Sales & Earnings Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy